Last updated on February 2018

Study of the Safety Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2 mg/kg IV Administered Every 4 Weeks in Fabry Disease Patients


Brief description of study

This open-label switchover study will assess the safety, efficacy, and pharmacokinetics of pegunigalsidase alfa (PRX-102) 2 mg/kg administered every 4 weeks for 52 weeks in Fabry patients previously treated with ERT: agalsidase alfa or agalsidase beta for at least 3 years. Safety and efficacy exploratory endpoints will be evaluated throughout the study period and pharmacokinetics will be obtained on Day 1 and Week 52.

Detailed Study Description

This is an open-label switchover study to assess the safety, efficacy, and pharmacokinetics of pegunigalsidase alfa treatment of 2 mg/kg every 4 weeks in patients previously treated with enzyme-replacement therapy (ERT): agalsidase alfa or agalsidase beta, for at least 3 years and on a stable dose (>80% labelled dose/kg) for at least the last 6 months. Following screening, patients will be enrolled and switched from their current ERT (approximately 15 patients on each ERT) to receive intravenous (IV) infusions of pegunigalsidase alfa 2 mg/kg every 4 weeks for 52 weeks (total of 14 infusions). At the time of enrollment, premedication, if used for the agalsidase alfa or agalsidase beta infusions before enrollment, will be continued using the same premedication regimen during the first infusion with pegunigalsidase alfa and then will be gradually tapered down at the Investigator's discretion during the next infusions based on protocol-specified criteria. First infusions of pegunigalsidase alfa will be administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients will be able to receive their pegunigalsidase alfa infusions at a home care setup once the Investigator and Sponsor Medical Monitor agree that it is safe to do so. Safety and efficacy exploratory endpoints will be assessed throughout the 52-week study. In the case of clear clinical deterioration, the treatment may be changed to 1.0 mg/kg every 2 weeks at the Investigator's discretion and discussion with the Medical Monitor.

Clinical Study Identifier: NCT03180840

Contact Investigators or Research Sites near you

Start Over

Eric L Wallace, MD

UAB Medicine
Birmingham, AL United States
  Connect »

William Wilcox, MD

Emory University School of Medicine
Atlanta, GA United States
  Connect »

Bernat John, MD

University of Iowa Hospitals and Clinics
Iowa City, IA United States
  Connect »

Kahn Nedd, MD

Infusion Associates
Grand Rapids, MI United States
  Connect »

Robert Hopkin, MD

Cincinnati Children's Hospital Medical Center
Cincinnati, OH United States
  Connect »

Raphael Schiffmann, MD, MHSc

Institute of Metabolic Disease
Dallas, TX United States
  Connect »

Nicola Longo, MD, PhD

University of Utah Hospital & Clinics
Salt Lake City, UT United States
  Connect »

Ozlem Goker-Alpan, MD

O & O Alpan
Fairfax, VA United States
  Connect »

Francois Eyskens, MD

UZ Antwerpen
Edegem, Belgium
  Connect »

Michael L West, MD

Capital District Health Authority
Halifax, NS Canada
  Connect »

Ales Linhart, MD

Fakultn poliklinika V eobecn fakultn nemocnice v Praze
Praha 2, Czechia
  Connect »

Mirjam Langeveld, MD

Academisch Medisch Centrum
Amsterdam, Netherlands
  Connect »

Camilla Tøndel, MD

Helse Bergen HF Haukeland Universitetssykehus
Bergen, Norway
  Connect »

Pilar Giraldo, MD

Hospital Quir n Floresta
Zaragoza, Spain
  Connect »

Fatih Ezgu, MD

Gazi Universitesi Tip Fakultesi Cocuk Sagligi ve Hastaliklari Anabilim Dali
Ankara, Turkey
  Connect »

Patrick Deegan, MD

Addenbrooke's Hospital
Cambridge, United Kingdom
  Connect »

Tarekegn G Hiwot, MD

University of Birmingham, Institute of Metabolism and Systems Research
Edgbaston, United Kingdom
  Connect »

Robin Lachmann, MD

University College London Hospitals
London, United Kingdom
  Connect »

Derralynn Hughes, MD

The Royal Free Hospital
London, United Kingdom
  Connect »

Ana Jovanovic, MD

Salford Royal
Salford, United Kingdom
  Connect »